PRESS-NEWS.org - Press Release Distribution
FREE PRESS RELEASES DISTRIBUTION

Dana-Farber researchers present key studies at ASCO annual meeting

Innovative advances in kidney cancer and melanoma among top research presented

2021-05-20
(Press-News.org) BOSTON - Dana-Farber Cancer Institute researchers are presenting dozens of research studies at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO). The studies will be presented during the virtual program on June 4-8, 2021. ASCO is the world's largest clinical cancer research meeting, attracting more than 30,000 oncology professionals from around the world.

Toni K. Choueiri, MD, the director of the Lank Center for Genitourinary Oncology at Dana-Farber, will present results from the randomized, double-blind, phase III KEYNOTE-564 trial evaluating pembrolizumab versus placebo after surgery in patients with renal cell carcinoma (abstract LBA5) during ASCO's Plenary Session on Sunday, June 6, 2021, 1:00pm-4:00pm ET. The plenary session features five studies deemed to have the greatest potential impact on patient care.

F. Stephen Hodi, MD, the director of the Melanoma Center and Center for Immuno-Oncology at Dana-Farber is co-senior author on the RELATIVITY-047 study evaluating combination treatment with two immunotherapies (relatlimab plus nivolumab) versus nivolumab alone in first-line treatment for patients with advanced melanoma (abstract 9503). Findings from the RELATIVITY-047 study will be presented during the Melanoma/Skin Cancers Oral Abstract Session on Sunday, June 6, 2021, 8:00am-11:00am ET. The study is included in the ASCO Press Program.

Other key research shows new treatments and diagnostic advances in lung cancer, leukemia, head and neck cancer, pediatrics, and many others. Some of the research highlights include:

Antibody drug conjugate shows promise against non-small cell lung cancer resistant to targeted therapy

An antibody fused to a targeted drug has produced impressive results in a Phase I clinical trial involving patients with advanced non-small cell lung cancer (NSCLC) whose tumors had become resistant to a standard targeted therapy. Dana-Farber's Pasi A. Ja?nne, MD, PhD, is lead author of the study.

The trial evaluated the safety and effectiveness of patritumab deruxtecan, an antibody drug conjugate consisting of an antibody targeting the protein HER3 and an inhibitor of the topoisomerase 1 enzyme, in 57 patients whose NSCLC carried an EGFR gene mutation but no longer responded to EGFR-targeting drugs. Patients who become resistant to such drugs and to platinum-based chemotherapy usually have few treatment options.

After a median treatment time of 5.5 months, 39% of the participants had a confirmed clinical response to the conjugate - a reduction in tumor size or extent. Among these patients, the median progression-free survival was 8.2 months. The antitumor effect occurred in patients whose resistance to EGFR inhibitors arose from a range of molecular mechanisms and in those with no clear identifiable resistance mechanism.

The most common severe side effects were decreased blood platelet counts, lowered counts of neutrophils (a type of white blood cell), and fatigue - all consistent with previous safety studies.

The results have prompted investigators to open a Phase 2 trial of the conjugate for patients with EGFR-mutant NSCLC whose disease has become resistant to EGFR-targeting drugs and chemotherapy.

Title: Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) Abstract: 9007 Presenter: Pasi A. Ja?nne, MD, PhD Session/Time: Oral Abstract Session: Lung Cancer - Non-Small Cell Metastatic; Broadcasting: June 4, 1:00pm-4:00pm

PET scans following initial treatment help many patients with bulky early-stage Hodgkin lymphoma avoid radiotherapy

Many early-stage patients with bulky classic Hodgkin lymphoma (cHL) can avoid radiotherapy treatment and still have excellent outcomes, according to a clinical study in which treatment was adapted to findings on PET imaging. Bulky disease - characterized by large tumors typically in the center of the chest - is associated with poorer outcomes in cHL and is traditionally treated with radiotherapy following chemotherapy. However, radiation treatment to the chest can have long-term toxic effects including an increased risk of breast cancer and heart problems.

The results, presented by Ann LaCasce, MD, MMSc, of Dana-Farber, included 94 patients with stage IA-IIB cHL and disease bulk greater than 10 cm or .33 maximum intrathoracic diameter on chest X-ray. Patients received two cycles of chemotherapy (ABVD) and then underwent PET imaging. Patients whose disease showed uptake less than liver on interim PET scan (PET2-) - 78% of the patients -- received four additional cycles of chemotherapy, but no radiotherapy. Patients classed as PET2+ received intensified chemotherapy with four cycles of escBEACOPP plus radiation therapy.

The estimated progression-free survival (PFS) was 93.1% in the PET2- patients and 89.7% in PET2+ patients. With a median follow-up of 5.5 years, estimated 3-year overall survival was 98.6% in PET2- patients and 94.4% in PET2+ patients. (Overall survival was not a primary or secondary outcome of the study).

The investigators said the PET-adapted approach achieved excellent PFS outcomes "that allowed omission of radiotherapy in 78 percent of patients." The PET2+ patients who received BEACOPP and radiotherapy "did not have inferior outcomes."

Title: CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL) Abstract: 7507 Presenter: Ann S. LaCasce, MD, MMSc Session/Time: Oral Abstract Session: Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia; Broadcasting: June 7, 11:30am-2:30pm

Additional cycle of pembrolizumab before surgery improves response rates in locally advanced head and neck cancer

Increasing neoadjuvant pembrolizumab from one to two cycles prior to surgery improved pathological response rates in patients with surgically resectable locally advanced, HPV-negative head and neck squamous cell carcinoma, reported Ravindra Uppaluri, MD, PhD, Dana-Farber/Brigham and Women's Cancer Center. A previous study in which patients (36 total) received one neoadjuvant cycle of pembrolizumab followed by surgery two to three weeks later yielded a 22% rate of >50% pathologic response (tumor cell death and other evidence of response designated as pTR-2) and a 22% pTR-1 rate (10-49% pathologic response). The new report was on a 28-patient phase 2 trial in which patients received two cycles of pembrolizumab 42 and 21 days prior to surgery. Twelve of 28 patients (43%) experienced a pTR-2 and four (16%) of these patients had a major pathologic response including 1 complete response at the primary site.

Neoadjuvant therapy was well tolerated and clinical outcomes in this advanced disease population were excellent with only one recurrence noted to date. The researchers said the data suggest that the frequency of pathologic responses to neoadjuvant pembrolizumab can be improved by increasing the number of cycles and the treatment interval.

Title: Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC) Abstract: 6008 Presenter: Ravindra Uppaluri, MD, PhD Session/Time: Oral Abstract Session: Head and Neck Cancer; Broadcasting: June 7, 2:45pm-5:45pm

Molecular profiling of tumor tissue can benefit many young patients with cancer, study suggests

Testing solid tumors for genetic changes that can be targeted by drugs has revolutionized the treatment of many adults with cancer. New research by scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center suggests it can have significant benefits for many younger patients as well.

Alanna J. Church, MD, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, will present results from the GAIN/iCat2 consortium study, which is evaluating the use of genomic profiling of solid tumors in children and young adults. The report includes data on 345 study participants with molecular profiling, who were diagnosed with solid, non-brain tumors at age 30 or younger. 299 patients (87%) had at least one genomic alteration that could impact the diagnosis, treatment, and prognosis of their disease, the researchers found.

Thirty-one patients were treated with matched targeted therapies and six patients had extraordinary responses to treatment. All patients with extraordinary responses matched to a gene fusion, and 78% of diagnostically significant alterations were fusions.

Molecular tumor profiling has a significant impact on diagnosis and treatment recommendations for young patients with solid tumors. These results emphasize the importance of fusion detection for patients with sarcomas and rare tumors, said Church, the lead author of the study, which was the highest rated pediatric oncology abstract at the ASCO conference, and winner of the Conquer Cancer Nachman Award.

Title: Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study
Abstract: 10005
Presenter: Alanna J. Church, MD
Session Time: Oral Abstract Session: Pediatric Oncology I; Broadcasting: June 5, 10:00am-1:00pm

INFORMATION:

A full list of Dana-Farber Oral Presentations at the 2021 ASCO Annual Meeting is available here.

Additionally, Dana-Farber researchers are recipients of ASCO's Special Awards, the Society's highest honors.

Jennifer A. Ligibel, MD, director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living and the director of the Center for Faculty Well-Being at Dana-Farber, is the recipient of the Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award.

Tracy A. Balboni, MD, MPH, FAAHPM, radiation oncologist at Dana-Farber/Brigham and Women's Cancer Center and a professor of radiation oncology at Harvard Medical School, is the recipient of the Walther Cancer Foundation Palliative and Supportive Care in Oncology Endowed Award. Her award lecture is available for on-demand viewing during the ASCO conference, starting June 4, 2021, 9:00am ET.

For all ASCO-related media inquiries, call or email Victoria Warren, 617-939-5531, Victoria_Warren@dfci.harvard.edu. Follow the meeting live on Twitter using the hashtag #ASCO21 and follow Dana-Farber on Twitter at @DanaFarberNews.

About Dana-Farber Cancer Institute Dana-Farber Cancer Institute is one of the world's leading centers of cancer research and care. Dana-Farber's mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. The Institute provides the latest treatments in cancer for adults through Dana-Farber/Brigham and Women's Cancer Center and for children through Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 6 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care. As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 therapeutic and non-therapeutic clinical trials.



ELSE PRESS RELEASES FROM THIS DATE:

Solid-state batteries line up for better performance

Solid-state batteries line up for better performance
2021-05-20
CHAMPAIGN, Ill. -- Solid-state batteries pack a lot of energy into a small space, but their electrodes are not good at keeping in touch with their electrolytes. Liquid electrolytes reach every nook and cranny of an electrode to spark energy, but liquids take up space without storing energy and fail over time. Researchers are now putting solid electrolytes in touch with electrodes made of strategically arranged materials - at the atomic level - and the results are helping drive better solid-state battery technologies. A new study, led by University of Illinois Urbana-Champaign materials science and engineering professor Paul Braun, postdoctoral research associate Beniamin Zahiri, and Xerion Advanced Battery Corp. director of research and development ...

UMD collaborates across disciplines to characterize the economics and value of pollination

UMD collaborates across disciplines to characterize the economics and value of pollination
2021-05-20
The University of Maryland (UMD) co-published a new review paper in the Annual Review of Resource Economics to examine pollinators from both an economic and ecological perspective, providing much needed insight into the complexities of valuing pollination. Pollinators are not only a critical component of a healthy ecosystem, but they are also necessary to produce certain foods and boost crop yields. While native and wild pollinators (whether they be certain bee species, other insects and animals, or just the wind) still play an important role, managed honey bee colonies are commercially trucked around the U.S. to meet the need for pollination services in agricultural products. Recent reports of ...

Science moves closer to diet that improves metabolic health without sharp cuts in calories

Science moves closer to diet that improves metabolic health without sharp cuts in calories
2021-05-20
BATON ROUGE, Louisiana - A diet that improves the biomarkers of metabolic health, and that could potentially slow the aging process, has moved a step closer to reality. "We've known for years that restricting the amino acid methionine in the diet produces immediate and lasting improvements in nearly every biomarker of metabolic health," said Thomas W. Gettys, PhD, Professor and Director, Nutrient Sensing and Adipocyte Signaling Laboratory at Pennington Biomedical Research Center. "The problem is that methionine-restricted diets have been difficult to implement because they taste so bad." Until now. Restricting methionine normally involves diets formulated with elemental (e.g., individual) amino acids. Individual amino acids are the building blocks ...

Weight cycling linked to increased sleep problems in women

2021-05-20
May 20, 2021 - Women with a history of weight cycling - losing and regaining 10 pounds or more, even once - have increased rates of insomnia and other sleep problems, reports a study in The Journal of Cardiovascular Nursing, official journal of the Preventive Cardiovascular Nurses Association. The journal is published in the Lippincott portfolio by Wolters Kluwer. "History of weight cycling was prospectively associated with several measures of poor sleep, including short sleep duration, worse sleep quality, greater insomnia, greater sleep disturbances, ...

Airborne radar reveals groundwater beneath glacier

Airborne radar reveals groundwater beneath glacier
2021-05-20
Melting glaciers and polar ice sheets are among the dominant sources of sea-level rise, yet until now, the water beneath them has remained hidden from airborne ice-penetrating radar. With the detection of groundwater beneath Hiawatha Glacier in Greenland, researchers have opened the possibility that water can be identified under other glaciers from the air at a continental scale and help improve sea-level rise projections. The presence of water beneath ice sheets is a critical component currently missing from glacial melt scenarios that may greatly impact how quickly seas rise - for example, by enabling big chunks of ice to calve ...

Forensic memory detection tests less effective in older adults

2021-05-20
New research led by the University of Kent's School of Psychology has found that some brain activity methods used to detect incriminating memories do not work accurately in older adults. Findings show that concealed information tests relying on electrical activity of the brain (electroencephalography [EEG]) are ineffective in older adults because of changes to recognition-related brain activity that occurs with aging. EEG-based forensic memory detection is based on the logic that guilty suspects will hold incriminating knowledge about crimes they have committed, and therefore their brains will elicit a recognition response ...

The entire genome from Peştera Muierii 1 sequenced

The entire genome from Peştera Muierii 1 sequenced
2021-05-20
For the first time, researchers have successfully sequenced the entire genome from the skull of Peştera Muierii 1, a woman who lived in today's Romania 35,000 years ago. Her high genetic diversity shows that the out of Africa migration was not the great bottleneck in human development but rather this occurred during and after the most recent Ice Age. This is the finding of a new study led by Mattias Jakobsson at Uppsala University and being published in Current Biology. "She is a bit more like modern-day Europeans than the individuals in Europe 5,000 years earlier, but the difference is much less than we had thought. We can see that she is not a direct ancestor of modern Europeans, but she is a predecessor of the hunter-gathers that lived in Europe until the end of the last ...

Newly identified antibody can be targeted by HIV vaccines

2021-05-20
DURHAM, N.C. - A newly identified group of antibodies that binds to a coating of sugars on the outer shell of HIV is effective in neutralizing the virus and points to a novel vaccine approach that could also potentially be used against SARS-CoV-2 and fungal pathogens, researchers at the Duke Human Vaccine Institute report. In a study appearing online May 20 in the journal Cell, the researchers describe an immune cell found in both monkeys and humans that produces a unique type of anti-glycan antibody. This newly described antibody has the ability to attach ...

Survival of migrating juvenile salmon depends on stream flow thresholds

Survival of migrating juvenile salmon depends on stream flow thresholds
2021-05-20
Juvenile salmon migrating to the sea in the Sacramento River face a gauntlet of hazards in an environment drastically modified by humans, especially with respect to historical patterns of stream flow. Many studies have shown that survival rates of juvenile salmon improve as the amount of water flowing downstream increases, but "more is better" is not a useful guideline for agencies managing competing demands for the available water. Now fisheries scientists have identified key thresholds in the relationship between stream flow and salmon survival that can serve as actionable targets for managing water resources in the Sacramento River. The new analysis, published May 19 in Ecosphere, revealed nonlinear ...

Understanding light-activated proteins in order to improve them

Understanding light-activated proteins in order to improve them
2021-05-20
Today, proteins that can be controlled with light are a widely used tool in research to specifically switch certain functions on and off in living organisms. Channelrhodopsins are often used for the technique known as optogenetics: When exposed to light, these proteins open a pore in the cell membrane through which ions can flow in; this is how nerve cells can be activated. A team from the Centre for Protein Diagnostics (PRODI) at Ruhr-Universität Bochum has now used spectroscopy to discover a universal functional mechanism of channelrhodopsins that determines their efficiency as a channel and thus as an optogenetic tool. The researchers led by Professor Klaus ...

LAST 30 PRESS RELEASES:

Scientists model 'true prevalence' of COVID-19 throughout pandemic

New breakthrough to help immune systems in the fight against cancer

Through the thin-film glass, researchers spot a new liquid phase

Administering opioids to pregnant mice alters behavior and gene expression in offspring

Brain's 'memory center' needed to recognize image sequences but not single sights

Safety of second dose of mRNA COVID-19 vaccines after first-dose allergic reactions

Changes in disparities in access to care, health after Medicare eligibility

Use of high-risk medications among lonely older adults

65+ and lonely? Don't talk to your doctor about another prescription

Exosome formulation developed to deliver antibodies for choroidal neovascularization therapy

Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose

Plant root-associated bacteria preferentially colonize their native host-plant roots

Rare inherited variants in previously unsuspected genes may confer significant risk for autism

International experts call for a unified public health response to NAFLD and NASH epidemic

International collaboration of scientists rewrite the rulebook of flowering plant genetics

Improving air quality reduces dementia risk, multiple studies suggest

Misplaced trust: When trust in science fosters pseudoscience

Two types of blood pressure meds prevent heart events equally, but side effects differ

New statement provides path to include ethnicity, ancestry, race in genomic research

Among effective antihypertensive drugs, less popular choice is slightly safer

Juicy past of favorite Okinawan fruit revealed

Anticipate a resurgence of respiratory viruses in young children

Anxiety, depression, burnout rising as college students prepare to return to campus

Goal-setting and positive parent-child relationships reduce risk of youth vaping

New research identifies cancer types with little survival improvements in adolescents and young adul

Oncotarget: Replication-stress sensitivity in breast cancer cells

Oncotarget: TERT and its binding protein: overexpression of GABPA/B in gliomas

Development of a novel technology to check body temperature with smartphone camera

The mechanics of puncture finally explained

Extreme heat, dry summers main cause of tree death in Colorado's subalpine forests

[Press-News.org] Dana-Farber researchers present key studies at ASCO annual meeting
Innovative advances in kidney cancer and melanoma among top research presented